MAS1 and neoplasm: In the Sunitinib-treated subcutaneous xenograft tumor model, MAGI3 overexpression led to significantly slowed tumor growth, reduced weight, and diminished levels of phosphorylated ERK and ki67, affirming the pivotal role of the MAS/MAGI3 axis in regulating Sunitinib sensitivity in ccRCC cells (Fig. 7I–L).